Translocator protein distribution volume predicts reduction of symptoms during open-label trial of celecoxib in major depressive disorder

S Attwells, E Setiawan, PM Rusjan, C Xu, C Hutton… - Biological …, 2020 - Elsevier
Background Gliosis is common among neuropsychiatric diseases, but the relationship
between gliosis and response to therapeutics targeting effects of gliosis is largely unknown …
被引用次数：38 相关文章

Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder.

S Attwells, E Setiawan, PM Rusjan, C Xu… - Biological …, 2020 - europepmc.org
Background Gliosis is common among neuropsychiatric diseases, but the relationship
between gliosis and response to therapeutics targeting effects of gliosis is largely unknown …

Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder

S Attwells, E Setiawan, PM Rusjan… - Biological …, 2020 - biologicalpsychiatryjournal.com
Background Gliosis is common among neuropsychiatric diseases, but the relationship
between gliosis and response to therapeutics targeting effects of gliosis is largely unknown …

Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder

S Attwells, E Setiawan, PM Rusjan… - Biological …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Gliosis is common among neuropsychiatric diseases, but the relationship
between gliosis and response to therapeutics targeting effects of gliosis is largely unknown …